INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
Real-time Estimate Cboe BZX  -  05/24 10:55:45 am EDT
43.28 USD   -8.54%
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
05/09JMP Securities Lowers Intellia Therapeutics Price Target to $110 From $165, Market Outperform Rating Kept
MT
05/09Oppenheimer Adjusts Intellia Therapeutics' Price Target to $130 From $160, Maintains Outperform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
46.94(c) 47.71(c) 47.74(c) 47.32(c) 43.7 Last
942 310 876 746 1 142 248 664 731 219 311 Volume
-2.88% +1.64% +0.06% -0.88% -7.65% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 46,1 M - -
Net income 2022 -426 M - -
Net cash position 2022 771 M - -
P/E ratio 2022 -8,00x
Yield 2022 -
Sales 2023 40,5 M - -
Net income 2023 -437 M - -
Net cash position 2023 644 M - -
P/E ratio 2023 -8,15x
Yield 2023 -
Capitalization 3 589 M 3 589 M -
EV / Sales 2022 61,1x
EV / Sales 2023 72,7x
Nbr of Employees 485
Free-Float 90,3%
More Financials
Company
Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular... 
More about the company
Ratings of Intellia Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about INTELLIA THERAPEUTICS, INC.
05/11Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
RE
05/09JMP Securities Lowers Intellia Therapeutics Price Target to $110 From $165, Market Outp..
MT
05/09Oppenheimer Adjusts Intellia Therapeutics' Price Target to $130 From $160, Maintains Ou..
MT
05/06Raymond James Adjusts Intellia Therapeutics' Price Target to $105 from $181, Keeps Outp..
MT
05/06Guggenheim Adjusts Price Target for Intellia Therapeutics to $120 From $150, Maintains ..
MT
05/06Credit Suisse Lowers Intellia Therapeutics' PT to $98 from $100, Warns Negative Data Co..
MT
05/05Wedbush Lowers Price Target for Intellia Therapeutics to $55 From $108, Maintains Neutr..
MT
05/05INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/05Intellia Therapeutics Q1 Loss Widens, Revenue Rises
MT
05/05TRANSCRIPT : Intellia Therapeutics, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/05Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Rec..
AQ
05/03INTELLIA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/03Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors
CI
05/02Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
AQ
More news
News in other languages on INTELLIA THERAPEUTICS, INC.
05/11Le rachat de Biohaven par Pfizer, pour 11,6 milliards de dollars, pourrait susciter d'a..
05/05La perte d'Intellia Therapeutics au premier trimestre se creuse, mais les revenus augme..
05/05Intellia Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
05/03Intellia Therapeutics, Inc. nomme Muna Bhanji à son conseil d'administration
05/02Intellia Therapeutics, Inc. présente des données précliniques démontrant les avancées d..
More news
Analyst Recommendations on INTELLIA THERAPEUTICS, INC.
More recommendations
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 47,32 $
Average target price 135,76 $
Spread / Average Target 187%
EPS Revisions
Managers and Directors
John M. Leonard President, Chief Executive Officer & Director
Glenn Goddard Treasurer, Chief Financial & Accounting Officer
Frank A. G. M. Verwiel Chairman
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Eliana Clark Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
INTELLIA THERAPEUTICS, INC.-59.98%3 589
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688